2017 American Transplant Congress
Enhanced Hepatic Engraftment of Stem Cell Derivatives Using Magnetic Targeting into Structurally Normal Liver.
Surgery, University of Texas Medical Branch, Galveston, TX
Attaining consistent robust engraftment in the structurally normal liver is an obstacle for cellular transplantation. Until now, many therapies to increase engraftment after cellular transplantation…2017 American Transplant Congress
Everolimus Is Associated with Less Weight Gain Than Tacrolimus Two Years Following Liver Transplantation: Results of a Randomized Multicenter Study.
Weight gain after liver transplant may lead to post-transplant complications, and is a risk factor for post-transplant metabolic syndrome (PTMS), cardiovascular events, and renal insufficiency.…2017 American Transplant Congress
Impact of Dialysis During the Transplant Admission on Transplant and Post-Transplant Cost of Care.
This study examines the impact of dialysis during the transplant admission on total cost of transplant and one year post-transplant care for kidney, liver, and…2017 American Transplant Congress
Increasing Liver Transplant Waitlist Dropout for Hepatocellular Carcinoma with Widening Geographical Disparities: Implications for Organ Allocation.
Given the increasing incidence of hepatocellular carcinoma (HCC) and regional differences in liver transplant (LT) rates for HCC, we used the United Network for Organ…2017 American Transplant Congress
A Multi-Center Experience of Direct Acting Anti-Viral Agents in HCV Positive Patients Receiving HCV Positive Livers.
Background: HCV cirrhosis is the leading indication for liver transplantation in the U.S. The development of direct acting anti-viral agents (DAAs) has changed the approach…2017 American Transplant Congress
Results of the Initial Phase of the Portable Organ Care System (OCS™) Liver PROTECT Pivotal Trial.
PurposeThe OCS Liver PROTECT Trial is a prospective, international, randomized controlled trial to evaluate the impact of using portable ex-vivo warm, oxygenated blood perfusion using…2017 American Transplant Congress
The Objective Liver Frailty Index Significantly Improves the Clinician “Eyeball Test” to Predict Mortality in Liver Transplant Candidates.
Background: Frailty is a critical determinant of waitlist outcomes. The most commonly-used test to assess frailty in liver transplant (LT) candidates is the “eyeball test”,…2017 American Transplant Congress
Liver Mesenchymal Stem Cells Inhibit T Cell Alloresponses.
Clinical and histologic evidence suggest that the liver allograft induces alloimmune hyporesponsiveness in the recipient. Mesenchymal stem cells (MSC) are multipotent non-hematopoietic stromal cells with…2017 American Transplant Congress
Is There Any Difference Between ABO-Incompatible and ABO-Compatible Liver Transplantation? Oncologic Aspect.
Introduction: Liver transplantation (LT) is increasing treatment option for hepatocellular carcinoma (HCC) in East Asia. Over-immunosuppression is risk factor for oncologic outcome after transplantation and…2017 American Transplant Congress
Epidemiology and Clinical Outcomes of Mycobacterium tuberculosis in Liver Transplant Recipients in an Intermediate Tuberculosis-Endemic Area.
BackgroundSolid organ transplant recipients are considered a high risk group for Mycobacterium tuberculosis(TB). In Korea, the incidence of tuberculosis was estimated to be 80 per…
- « Previous Page
- 1
- …
- 132
- 133
- 134
- 135
- 136
- …
- 180
- Next Page »